Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02923180
Recruitment Status : Active, not recruiting
First Posted : October 4, 2016
Last Update Posted : September 23, 2019
Sponsor:
Collaborator:
MacroGenics
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : October 2021